Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
Johann Gudjonsson, MD, PhD
University of Michigan, Department of Dermatology
Ann Arbor, Michigan, United States
IPC Board Member
BioPUBLICATION
Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast. Grigsby KB, Mangieri RA, Roberts AJ, et al. J Clin Invest. 2023 Mar 15;133(6):e159103. doi: 10.1172/JCI159103. PMID: 36656645; PMCID: PMC10014105.
Why this article was chosen
Commentary
A recently published article in the Journal of Clinical Investigation demonstrated that apremilast, a commonly used drug to treat psoriasis, is associated with reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence.1 These findings may have major implications regarding the treatment of psoriasis, where there is a clear link between disease and alcohol use,2,3 and where apremilast is frequently used for treatment.4
Genetic variants in the PDE4B gene locus have been implicated with both alcohol and nicotine dependence in a genome-wide association study,5 and another PDE4 inhibitor, rolipram, has been shown to dose-dependently reduce self-administration of alcohol in a mouse model of alcohol consumption.6 PDE4 is expressed in the central nervous system, in the nucleus accumbens, a brain region associated with motivation and emotional processes.7 In the study highlighted here, the authors set out to determine if apremilast, a PD4 inhibitor, affects alcohol consumption in both mouse models of alcohol drinking and a double-blind, placebo-controlled proof-of-concept study in a moderate-size cohort composed of 24 women and 27 men, with a history of heavy drinking for an average ten years prior to the study. The findings demonstrated that apremilast reduced the number of drinks per day relative to the placebo and the probability of a heavy drinking day.1 The group further showed that apremilast alters the intrinsic excitability of nucleus accumbens-derived neurons expressing dopamine receptor D1, providing a mechanistic basis for its effect on alcohol consumption.1
Alcohol use disorder is frequent in patients with psoriasis and found in up to 8.6% of patients with psoriasis,2 and up to 23.8% of been reported to be high-risk drinkers.3 Furthermore, alcohol consumption has been shown to correlate with psoriasis severity.2 This also could relate to weight loss mechanisms in psoriasis, which principally relates to decreased abdominal subcutaneous fat, independent of its effect on psoriatic disease activity.8 Thus, the implications of this study on psoriasis management could be substantial and may help guide treatment in psoriasis patients with concomitant addiction problems. However, this will need to be confirmed and validated in future studies.
References
Categories
Recent Posts
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)
Also Read
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
Focus on Psoriasis: A Report from the 2023 American Academy of Dermatology (AAD) Annual Meeting
The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in New Orleans, LA, and is the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. This report includes 13 summaries of talks focusing on psoriasis.
Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
Subscribe to the IPC Newsletter